Latest & greatest articles for mometasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on mometasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on mometasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for mometasone

1. Mometasone

Mometasone Top results for mometasone - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for mometasone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Mometasone Furoate (Asmanex Twisthaler) for asthma. It is inhaled, but does not aspire...for something more

Mometasone Furoate (Asmanex Twisthaler) for asthma. It is inhaled, but does not aspire...for something more 2015. DAR No 2: Mometasone Furoate. Asmanex Twisthaler® for asthma management - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DAR No 2: Mometasone Furoate. Asmanex Twisthaler® for asthma management DAR No 2: Mometasone Furoate. Asmanex Twisthaler® for asthma management Content tools Share it It is inhaled, but does not aspire (...) ...for something more Mometasone furoate is an inhaled glucocorticoid indicated in the maintenance treatment of persistent asthma. No advantage has been shown in terms of relevant clinical outcomes with respect to other inhaled corticosteroids. The profile of adverse effects and the administration regimen of mometasone are similar to that of other inhaled corticoids. Enviar comentario You can send us a comment or suggestion and we will respond to most frequently asked questions Competing interests (complete

Drug and Therapeutics Bulletin of Navarre (Spain)2015

3. Asmanex HFA (mometasone furoate) Inhalation Aerosol

Asmanex HFA (mometasone furoate) Inhalation Aerosol Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Asmanex HFA (mometasone furoate) Inhalation Aerosol Company: Merck Sharp & Dohme Corp. Application No.: 205641 Approval Date: 4/25/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2014

7. Dulera (mometasone furoate and formoterol fumarate) Inhalation Aerosol

Dulera (mometasone furoate and formoterol fumarate) Inhalation Aerosol Drug Approval Package: Dulera (mometasone furoate and formoterol fumarate) NDA #022518 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Dulera (mometasone furoate and formoterol fumarate) Inhalation Aerosol 100/5 and 200/5 micrograms Company: Schering Corporation Application No.: 022518 Approval Date: 06/22/2010 Persons with disabilities having problems accessing the PDF files

FDA - Drug Approval Package2010

8. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis: meta-analysis of randomized, double-blind, placebo-controlled, clinical trials

Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis: meta-analysis of randomized, double-blind, placebo-controlled, clinical trials Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis: meta-analysis of randomized, double-blind, placebo-controlled, clinical trials Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis: meta-analysis of randomized, double-blind, placebo-controlled, clinical trials Penagos M (...) , Compalati E, Tarantini F, Baena-Cagnani CE, Passalacqua G, Canonica GW CRD summary The authors concluded that mometasone furoate nasal spray effectively reduced total and individual symptoms scores in patients with allergic rhinitis. This was a well-conducted and clearly reported review. The authors’ conclusions are likely to be reliable. Authors' objectives To evaluate the efficacy of mometasone furoate nasal spray (MFNS) in patients with allergic rhinitis. Searching MEDLINE, LILACS, SCOPUS

DARE.2008

9. Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo

Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin or placebo Article Text Therapeutics Mometasone furoate nasal spray was more effective for symptom relief of acute rhinosinusitis than amoxicillin

Evidence-Based Medicine (Requires free registration)2007

11. Mometasone furoate (Asmanex Twisthaler)

Mometasone furoate (Asmanex Twisthaler) Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium Mometasone furoate (Asmanex Twisthaler Ò ) (No. 79/03) Schering-Plough Summary of Recommendation 10 November, 2003 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland (...) . The recommendation is summarised as follows: Advice: following a full submission. Accepted for restricted use within NHS Scotland Mometasone is the fourth inhaled steroid licensed for treatment of asthma. It is available as a dry powder inhaler. It has a similar efficacy and adverse event profile to other currently available inhaled steroids. It is suitable for use as a second line agent following treatment failure on first line inhaled steroids. Professor David H Lawson Chairman

Scottish Medicines Consortium2003